TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

Most medicines used worldwide are off-patent products – generic or biosimilar versions of branded medicines offering the same quality, safety, and efficacy at a lower price. They are the ‘silent ...

The global supply chain for critical generic medicines faces increasing challenges. The skewed economics of the generic medicines market need to be corrected.

It is playing catch-up with a rival Lp(a) targeting antisense drug from Novartis and development partner Akcea, called pelacarsen, which is already in a phase 3 trial called HORIZON with major ...